Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

This study is testing whether a very precise form of radiation called stereotactic ablative radiotherapy (SABR) — which delivers high doses of radiation with pinpoint accuracy — can help control metastatic breast cancer that has spread to only a few places in the body (called oligometastatic disease). **You may be eligible if...** - You are 18 or older with breast cancer that has spread to 1–5 spots in up to two organs - Your cancer spread is confirmed by a PET-CT scan - Your cancer is stable or responding to your current treatment - Each cancer spot is no larger than 5 cm - You are reasonably active and have a life expectancy over 6 months **You may NOT be eligible if...** - You have more than 5 metastatic spots or involvement of more than 2 organs - Your primary breast tumor is not under control - You are too unwell to tolerate radiation treatment Talk to your doctor to see if this trial is right for you.